Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Morphine sulfate (MS) and pentobarbital (PB) stimulate growth hormone (GH) release in the rat in vivo, but not from enzymatically dissociated anterior pituitary cells in vitro. Somatostatin and thyrotropin-releasing factor (TRF) inhibit the in vivo release of GH induced by MS, with 50% inhibition at ca. 2.3 and 4.6 mug/100 g BW, respectively. Somatostatin and TRF similarly inhibit PB-induced GH release. Prostaglandin E2 stimulates GH release both in vivo and in vitro. Both of these responses are inhibited by somatostatin (50% inhibition at ca. 10 mug/100g BW), but neither is altered by TRF (100 mug/100g BW). Both normal and hypophysectomized rats receiving MS exhibited a rapid vibration of the tail immediately after administration of TRF (30 mug/100g BW). Structural analogs of TRF with low TSH-releasing activity did not inhibit GH release nor induced tail vibration in MS-treated rats. Pyroglutamyl-3-methyl-histidyl-prolinamide, with 8 times the hypophysiotropic potency of TRF, is similarly more potent than TRF in inhibiting GH release and inducing tail vibration in MS-treated rats. These results suggest the following: 1) MS and PB act at a central nervous system (CNS) site to release GH; 2) TRF may act at a CNS site to inhibit MS- and PB-induced GH release; 3) somatostatin has direct pituitary effects on inhibition of GH, but a CNS site of action cannot be excluded; and 4) TRF stimulates tail motor activity in MS-treated rats.
 ...
PMID:Growth hormone release in the rat: effects of somatostatin and thyrotropin-releasing factor. 81 Mar 43

The capacity of several potent pharmacological agents to increase growth hormone (GH) release was tested in young (3- to 4-month-old) and old (18- to 20-month-old) male Sprague-Dawley rats. Young and old animals were injected with alpha-methyl-p-tyrosine (250 mg/kg), a catecholamine synthesis inhibitor, followed 60 min later by the alpha-adrenergic receptor agonist, clonidine hydrochloride (150 micrograms/kg). Plasma GH levels increased to greater than 276 ng/ml by 30 and 50 min in young rats, whereas values never exceeded 130 ng/ml (p less than 0.01) in old rats. Piribedil methane sulfonate (1 mg/kg), a dopamine receptor agonist, significantly increased GH in young animals 60 min after injection (p less than 0.01), but had no effect in old rats. Morphine sulfate (5mg/kg) increased plasma GH concentration in young rats to greater than 400 ng/ml at 30, 50 and 70 min after injections, whereas values in old animals never exceeded 300 ng/ml (p less than 0.01). 15 min after injection of somatostatin antiserum No. 774 (5 ml/kg), plasma GH levels increased to greater than 750 ng/ml in both young and old rats. Administration of greater volumes of somatostatin antiserum (8 ml/kg) increased GH levels more in old than in young animals 30 and 45 min after injection (p less than 0.01). These results indicate that old male rats have less capacity to increase GH in response to agents that normally enhance GH release. This may be the result of a diminished number of affinity of post-synaptic neurotransmitter receptors, or to an increased release of somatostatin. Since somatostatin antiserum in creased H equally or to a greater extent on old that in young animals, aging rats may release more somatostatin or the pituitary may be more sensitive to the inhibitory effects of this hormone.
 ...
PMID:Effects of CNS active drugs and somatostatin antiserum on growth hormone release in young and old male rats. 611 31